Room-temperature synthesis of triple-cation green perovskite quantum dots for optoelectronic applications.

The development of multi-cation perovskite quantum dots (PQDs) is limited by the low availability of fitting A-site cations due to the unsuitable radii of a large gamut of amine cations. The impact of oversized or undersized cations on the perovskite structure is detrimental to the structural stabilization and electroluminescence efficiency of the PQDs. Researchers are actively seeking suitable-sized cations to mitigate perovskite defect formation and optimize charge carrier confinement within the PQDs.

Robot-Assisted Partial Nephrectomy for Multiple Allograft Renal Cell Carcinomas: A Case Report.

Background: Partial nephrectomy (PN) is strongly recommended as nephron-sparing surgery for T1 renal tumors. Although there have been some reports of robot-assisted PN (RAPN) for solitary allograft renal tumors, only a few cases of RAPN for multifocal allograft renal tumors have been reported. Herein, we report a case of a patient who underwent RAPN for multifocal allograft renal cell carcinoma (RCCs).

Aromatic 2,2-Diphenylethylamine Ligand Exchange of FACsPbBr Perovskite Nanocrystals for High-Efficiency Pure Green Light-Emitting Diodes.

Perovskite nanocrystals (NCs) with long alkyl ligands cannot easily form high-quality composite films owing to their poor dispersibility in π-conjugated small molecules and polymer host materials. In this study, we demonstrated that the aromatic ligand exchange of mixed-cation FACsPbBr NCs using 2,2-diphenylethylamine (DPEA) can not only enable the fabrication of high-efficiency light-emitting diodes (LEDs) but also allows dispersibility in host materials. The DPEA-NC film exhibited a pure green wavelength of 530 nm and a full width at half-maximum of 20.

Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era.

Background: The therapeutic benefit of immuno-oncology (IO) therapy for patients with advanced non-clear-cell renal cell carcinoma (nccRCC) remains unclear.

Patients And Methods: We reviewed clinical data from 93 patients with advanced nccRCC who received first-line systemic therapy including IO combination therapy and tyrosine kinase inhibitor (TKI) monotherapy at our affiliated institutions. Patients were divided based on the period when the treatment was implemented as the standard of care into the IO and TKI eras.

Prognostic Impact of the Administration of Antibiotics and Proton Pump Inhibitors in Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma.

Background/aim: The prognostic impact of the administration of antibiotics and proton pump inhibitors (PPIs) in immune checkpoint inhibitor (ICI) therapy for advanced cancer has recently been documented. However, how these drugs affect the outcomes of first-line ICI combination therapy for advanced renal cell carcinoma (RCC) remains unclear.

Patients And Methods: We retrospectively evaluated the data of 128 patients with RCC who received first-line ICI combination therapy.